Healthcare Equipment and Supplies
Company Overview of Arch Therapeutics, Inc.
Arch Therapeutics, Inc. operates as a life science medical device company. The company focuses on developing products by utilizing a novel approach to stop bleeding and control leaking during surgery and trauma care. Its lead product candidate includes AC5 Surgical Hemostatic Device, a biocompatible synthetic peptide, which comprises naturally occurring amino acids to achieve hemostasis in minimally invasive and open surgical procedures. The company was founded in 2006 and is headquartered in Wellesley, Massachusetts.
20 William Street
Wellesley, MA 02481
Founded in 2006
Key Executives for Arch Therapeutics, Inc.
Co-Founder, Chief Executive Officer, President and Director
Total Annual Compensation: $390.8K
Chief Financial Officer and Treasurer
Total Annual Compensation: $87.2K
Chief Operating Officer
Total Annual Compensation: $253.3K
Compensation as of Fiscal Year 2014.
Arch Therapeutics, Inc. Key Developments
Arch Therapeutics, Inc. Presents at Red Chip Global Online CEO Conference, Apr-22-2015 03:00 PM
Apr 20 15
Arch Therapeutics, Inc. Presents at Red Chip Global Online CEO Conference, Apr-22-2015 03:00 PM. Speakers: Terrence W. Norchi, Co-Founder, Chief Executive Officer, President and Director.
Arch Therapeutics Announces Favorable Preclinical Data from an Independent Study of AC5 Surgical Hemostatic Device Versus a Popular Fibrin Sealant
Apr 14 15
Arch Therapeutics, Inc. announced that an independent third party has obtained favorable data from a preclinical animal study that compared the hemostatic activity of AC5 with a popular and commercially available branded fibrin sealant that is indicated for use in controlling bleeding. In this study, full thickness penetrating wounds were surgically created in rat livers, which are highly vascularized parenchymal organs, and then either AC5TM or the fibrin sealant was applied in order to stop the bleeding. The time to hemostasis (TTH), which is the time required to stop bleeding, was measured. The average TTH after application of AC5 was significantly less than 30 seconds. The average TTH for the fibrin sealant was approximately 50% longer. AC5 was maintained at room temperature without requiring cold storage, whereas the fibrin sealant was maintained frozen during storage, in accordance with its prescribing directions. This is a common constraint of many commercial hemostatic agents that are derived from blood-products. Such products also require a multi-step preparation procedure prior to use. AC5 contains a self-assembling peptide comprising naturally occurring amino acids that are not sourced from humans or animals, whereas the fibrin sealant is made from pooled human plasma (blood product). Fibrin sealants and other products that are sourced from human or animal blood products can contain infectious agents, such as viruses and potentially the Creutzfeldt-Jakob disease (CJD) agent, which potentially can be transferred to a patient. The study group intends to submit the data for publication, at which time additional details would be made publicly available. This animal trial was conducted as part of an ongoing series of studies comparing AC5 with currently marketed hemostatic products that are used in surgical procedures.
Arch Therapeutics, Inc. Announces Positive Safety Results for AC5 Surgical Hemostatic Device in Preclinical Toxicity Studies
Mar 23 15
Arch Therapeutics, Inc. announced that the company obtained additional favorable preclinical data from two planned standardized medical device safety studies in which AC5 was assessed for toxicity to cells and for contamination from pyrogens (toxins that cause fever) produced by bacterial cells. The tests are major components of the panel of biocompatibility testing that medical devices must typically complet e successfullyprior to use in humans. In the cytotoxicity test, which is an in vitro study that assesses AC5 for toxicity to cells using cell cultures, AC5 tested in clinically relevant amounts was found to be non-toxic to cells (non-cytotoxic). In the pyrogenicity test, which is an in vitro study that assesses AC5 for the presence of pyrogens, AC5 tested in clinically relevant amounts was found to be non-pyrogenic, which is a desirable characteristic. Pyrogens, also known as bacterial endotoxins, are certain toxins made by bacteria. A product that were to contain sufficient amounts of pyrogen or other cell-toxins could trigger immune responses with the potential for tissue damage and significant harm to patients. The tests were conducted under guidelines provided by the International Organization for Standardization (ISO), the United States Pharmacopeia (USP), the American National Standards Institute (ANSI) and the Association for the Advancement of Medical Instrumentation (AAMI).
Similar Private Companies By Industry
Recent Private Companies Transactions
March 11, 2015